Abbott Laboratories enters its Q3 2026 earnings cycle with market-implied odds favoring 6% to 8% comparable sales growth, reflecting the company’s reaffirmed full-year 2026 guidance of 6.5% to 7.5% and expectations for sequential acceleration in the second half. Q2 comparable growth of 4.8% marked an improvement from prior quarters, supported by margin expansion of 100 basis points and momentum in Medical Devices, while the Exact Sciences acquisition contributes to reported revenue but is adjusted out of the comparable metric. Analysts project Q3 revenue near $12.7–13.0 billion against the $11.4 billion base from a year earlier, with key drivers including Nutrition recovery, Electrophysiology product launches, Core Laboratory stabilization after China headwinds, and Cancer Diagnostics expansion via Cologuard and new tests. The October 21 earnings release will provide the definitive data point, with any variance from the 6.5–7.5% annual path likely to shift near-term trader positioning.